The DFS of patients in the CEA-high group was significantly worse than that of patients in the CEA-low group among patients with ER-positive breast cancers (p < 0.0001), but there was no significant association in patients with ER-negative breast cancers (p = 0.11) (Fig. 3a, b). The gene discussed is CEACAM5; the disease is breast carcinoma.